Forest plot. by Junyin Pan (20700411)

Subjects:

Funnel plot. by Junyin Pan (20700411)

Subjects:

Each square gives extinction probability p (AB) or median population change d (CD) for 100 simulations at . by Alexandra M. Campbell (3284094)

FTY720 decreased viability, proliferation, and motility and induced apoptosis in human hepatoblastoma cells. by Laura L. Stafman (6577184)

“…<p>(A) Following 24 hours of treatment with FTY720, the viability of HuH6 cells measured using the alamarBlue cell viability assay was significantly decreased (LD₅₀ = 8.4 μM, p ≤ 0.05). …”

Frequency distribution of several indicators of women’s 3E along with its mean score and 95% confidence intervals. by Fatima Tuz-Zahura (12003987)

The Cincinnati water maze mirror version latency [s (mean ± SEM)] and number of errors (mean ± SEM) of proton irradiated and control rats. by Michael T. Williams (357796)

E₅₀ values. by Junxia Zhou (14381598)

Predicting pattern diversity decreases as a function of and . by Selim Haj Ali (21222613)

“…(a) and (b): Average negative predictive value for and , respectively for and . …”

Means and 95% confidence interval (CI) of all costs, benefits, and the difference in net benefits from the probabilistic reference case given in 2019 USD for 3 years for a 100-cow... by Marlena Waldbauer (18291223)

Minimum quorum sensing inhibitory concentrations (MQSICs), minimum inhibitory concentrations (MICs), and concentrations inhibiting 50% of violacein production (IC50s) of compounds... by Jean Paul Dzoyem (6424445)

Subjects:

Participants with virologic suppression or failure at week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. by Tosi M. Mwakyandile (16408705)

Subjects:

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

Subjects:

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Median changes in CD4 count, platelet activation, immune activation, and exhaustion markers from baseline through week 12 and week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Table1_Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part I: Genetic... by Veronika Todorovova (12157917)

“…Our data represent retrospective analysis of 50 years of specialised care in our center.</p><p>Patients and Methods: A group of 1236 FH patients (841 women, 395 men; 993 study subjects and 243 relatives; mean age 44.8 ± 16.7 years) included 154 FDB patients followed at the Lipid Clinic of the General University Hospital in Prague since the mid-1960s to the present. …”

Image1_Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part I: Genetic... by Veronika Todorovova (12157917)

“…Our data represent retrospective analysis of 50 years of specialised care in our center.</p><p>Patients and Methods: A group of 1236 FH patients (841 women, 395 men; 993 study subjects and 243 relatives; mean age 44.8 ± 16.7 years) included 154 FDB patients followed at the Lipid Clinic of the General University Hospital in Prague since the mid-1960s to the present. …”